The 8 constituents of our Psychedelic Drug Stocks Index continue to collectively show poor performance, down 4.6% more last week and now down 45.5% since the end of August.

The performances of the 5 cannabis categories ranged from -6.3% to -39.0% in September, and are now -13.6% to -67.0%, YTD, depending on the category. The S&P 500, in comparison, was -8.6% in September and is -24.8% YTD.

There are 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index. Most - but interestingly not all - were down for the week and/or the month.

The cannabis sector consists of 5 distinctly different categories and they each perform quite differently.

The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index were collectively down 10% in the past week. We also take a look at some therapy-clinic stocks.